Cargando…

Chromatin state profiling reveals PRC2 inhibition as a therapeutic target in NRAS–mutant melanoma

Recently, we have generated 284 epigenomic maps in melanoma. Using chromatin state profiling we identify an association of NRAS-mutants with bivalent Histone H3 lysine 27 trimethylation (H3K27me3) and broad H3K4me3 domains. Reprogramming of bivalent H3K27me3 occurs on critical invasive-regulators an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Terranova, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632323/ https://www.ncbi.nlm.nih.gov/pubmed/34859147 http://dx.doi.org/10.1080/23723556.2021.1986350

Ejemplares similares

Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy
por: Terranova, Christopher J., et al.
Publicado: (2021)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma
por: Reyes-Uribe, Patricia, et al.
Publicado: (2018)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells
por: Gao, Xuejun, et al.
Publicado: (2022)

Efficacy of Targeted Radionuclide Therapy Using [(131)I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
por: Akil, Hussein, et al.
Publicado: (2021)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

NRAS-mutant melanoma: current challenges and future prospect
por: Muñoz-Couselo, Eva, et al.
Publicado: (2017)

Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS
por: Kim, Jeong Eun, et al.
Publicado: (2018)

HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma
por: Parris, Joshua L.D., et al.
Publicado: (2021)

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin
por: Xia, Yun, et al.
Publicado: (2016)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
por: Dietsch, Bianca, et al.
Publicado: (2023)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines
por: Appleton, Kathryn M., et al.
Publicado: (2021)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

The interaction of PRC2 with RNA or chromatin is mutually antagonistic
por: Beltran, Manuel, et al.
Publicado: (2016)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
por: Vu, Ha Linh, et al.
Publicado: (2015)

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
por: Schuler, Martin, et al.
Publicado: (2022)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Activation of automethylated PRC2 by dimerization on chromatin
por: Sauer, Paul V., et al.
Publicado: (2023)

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2017)

Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA
por: Wang, Xueyin, et al.
Publicado: (2017)

α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid
por: Xia, Yun, et al.
Publicado: (2016)

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
por: Sanlorenzo, Martina, et al.
Publicado: (2018)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma
por: Nagler, Adi, et al.
Publicado: (2019)

Engaging chromatin: PRC2 structure meets function
por: Chammas, Paul, et al.
Publicado: (2019)

P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma
por: Banik, Ishani, et al.
Publicado: (2023)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
por: Gutierrez-Prat, Nuria, et al.
Publicado: (2022)

Evolving treatments and future therapeutic targets in desmoplastic melanoma
por: Hadfield, Matthew J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f476t1ha5atbeh9theqhfagtkv